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Summary
Objective: Basic calcium phosphate (BCP) crystals have been implicated in the pathogenesis of osteoarthritis (OA), in part because of their
ability to upregulate cyclooxygenase and prostaglandin E2 (PGE2) production. The aim of this work was to investigate the expression of ter-
minal PGE2 synthases and PGE2 receptors (EP) in BCP crystal-stimulated ﬁbroblasts.
Methods: Cultured ﬁbroblasts were stimulated with BCP crystals in vitro. mRNA expression was measured by real-time polymerase chain
reaction, and protein production by western blotting.
Results: Basal expression of microsomal prostaglandin E2 synthase 1 (mPGES1) in osteoarthritic synovial ﬁbroblasts (OASF) was found to be
30-fold higher than in human foreskin ﬁbroblasts (HFF). BCP crystals increased mPGES1 expression fourfold in HFF, but not in OASF. EP4
expression was downregulated twofold by BCP crystals in OASF, but not in HFF. Exogenous PGE2 also downregulated EP4 expression; this
effect was blocked by co-administration of L-161,982, a selective EP4 antagonist. While administration of exogenous PGE2 signiﬁcantly up-
regulated mPGES1 expression in OASF, mPGES1 expression was threefold higher in the OASF treated with BCP crystals and PGE2 as com-
pared with OASF treated with PGE2 alone.
Conclusions: The differing effects of BCP crystals on mPGES1 expression in HFF and OASF may be explained by BCP crystal-induced EP4
downregulation in OASF, likely mediated via PGE2. These data underline the complexity of the pathways regulating PGE2 synthesis and sug-
gest the existence of a compensatory mechanism whereby mPGES1 expression can be diminished, potentially reducing the stimulus for fur-
ther PGE2 production.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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synovium.Introduction
Prostaglandin E2 (PGE2) has been implicated in the patho-
genesis of osteoarthritis (OA) and inhibition of PG synthesis
via inhibition of cyclooxygenase (COX) by non-steroidal
anti-inﬂammatory drugs (NSAIDs) is a cornerstone of phar-
macologic therapy of OA. Prostaglandin E2 synthases
(PGES) catalyse the terminal step in synthesis of PGE2. Mi-
crosomal PGE synthase 1 (mPGES1) was ﬁrst described in
19991. Although mPGES1 is constitutively expressed in
certain cell types2e4, it is considered analogous to COX-2
in that it is generally expressed at low levels at baseline
and upregulated in response to pro-inﬂammatory stimuli.
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686expression and resultant PGE2 production has been re-
ported in many cell types following treatment with pro-in-
ﬂammatory stimuli1,5e11. mPGES2, a second form of
membrane-associated PGES with a distinct structure from
mPGES112, is expressed constitutively in a number of tis-
sues, in particular those in which mPGES1 expression is
relatively low. mPGES2 may couple with either COX-1 or
COX-213. Cytosolic PGES (cPGES) is expressed ubiqui-
tously and constitutively within the cytosol, and it is consid-
ered to preferentially convert COX-1-derived PGH2 to
PGE2
14. However, recent data in a mouse model have
cast uncertainty on the role of cPGES in PGE2 biosynthesis
in vivo15. While cPGES and mPGES2 are generally consti-
tutively expressed, in a rat adjuvant-induced arthritis model
mPGES2 was downregulated 2e3-fold and cPGES upregu-
lated 2e6-fold16.
A number of studies suggest a role for mPGES1 in arthri-
tis. The features of collagen-induced arthritis (CIA), includ-
ing synovitis, cartilage damage and bone erosion, are
attenuated in mPGES1 knockout mice17,18. Stichtenoth
Table I
Real-time PCR primer sequences for PGE2 synthases and
receptors
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upregulated by pro-inﬂammatory cytokines and downregu-
lated by dexamethasone in primary rheumatoid synovio-
cytes11. Westman et al. observed strong mPGES1
immunostaining in rheumatoid arthritis (RA) synovium19.
Kojima et al. showed that interleukin 1 beta (IL1b)-stimu-
lated mPGES1 expression in RA synoviocytes was downre-
gulated by NSAIDs20. This was reversed by addition of
exogenous PGE2, the administration of PGE2 receptor
(EP receptor) agonists or forskolin, a direct activator of ad-
enylate cyclase. Upregulation of mPGES1 by pro-inﬂamma-
tory cytokines such as IL1b in OA cartilage and OA
chondrocytes7,9,21 and synovial ﬁbroblasts5,22 has also
been demonstrated.
There are four main PGE2 receptors, referred to as EP
receptors (EP1, EP2, EP3, and EP4). The EP2 and EP4 re-
ceptors are the predominant EP receptors expressed in hu-
man RA synoviocytes20; binding to either of these receptors
leads to activation of adenylate cyclase and resultant cyclic
adenosine monophosphate (cAMP) accumulation23. McCoy
et al. characterised the disease severity of CIA in EP recep-
tor knockout mice, and found that features of CIA were
ameliorated only in the EP4/ mice24. Other relevant ef-
fects of PGE2- mediated via EP2 and/or EP4 receptors in-
clude modulation of bone turnover and of inﬂammatory
cytokine and chemokine production25e27. However, the pre-
cise effects of speciﬁc prostaglandin receptors in OA syno-
vium are unclear.
Basic calcium phosphate (BCP) crystals are predomi-
nantly composed of partially carbonate-substituted hydroxy-
apatite, and have been implicated in the pathogenesis of
OA. In vitro properties of BCP crystals that may contribute
to OA pathogenesis include the induction of mitogenesis,
stimulation of matrix metalloproteinase secretion, increased
nitric oxide production and upregulation of tumour necrosis
factor alpha (TNFa) and IL1b28. BCP crystals also cause an
increase in PGE2 production29e31, mediated by upregula-
tion of COX-1 and COX-232. Expression of mPGES1 in re-
sponse to BCP crystal stimulation has not previously been
studied. However, it has been reported that BCP crystals in-
duce early growth response 1 (Egr-1)33, the key transcrip-
tion factor in mPGES1 expression34. Furthermore, as
COX-2 and mPGES1 are co-ordinately induced under
most conditions studied to date and BCP crystals induced
COX-2 expression in human foreskin ﬁbroblasts (HFF)32
and OA synovial ﬁbroblasts (OASF)35, we hypothesized
that mPGES1 is also upregulated by BCP crystals. This
study aimed to examine the expression of PGES and EP re-
ceptors in OASF and to ascertain if this expression is inﬂu-
enced by BCP crystal stimulation.Gene of
interest
Primer sequence (50 / 30)Methods
mPGES1 Forward CCT AAC CCT TTT GTC GCC TG
Reverse CAG GTA GGC CAC GGT GTG TBCP CRYSTAL PREPARATIONmPGES2 Forward GGA GAA AGC TCG CAA CAA CTA AAT
Reverse AGC CTT CAT GGC TGG GTA GTA G
cPGES Forward AGC ATA AAA GAA CGG ACA GAT CAA
Reverse CGA CAC TAA GCC AAT TAA GCT TTG
EP1 Forward ATG GTG GGC CAG CTT GTC
Reverse GCC ACC AAC ACC AGC ATT G
EP2 Forward TGC CTT TCA CGA TTT TTG CA
Reverse TTA ATT GAT AAA AAC CTA AGA
GCT TGG ABCP crystals were synthesised by alkaline hydrolysis of brushite, as previ-
ously described36. Mineral prepared by this method has a calcium/phosphate
molar ratio of 1.59 and contains partially carbonate-substituted hydroxyapatite
mixed with octacalcium phosphate as determined by Fourier transform infra-
red spectroscopy. The crystals were weighed into vials and rendered pyrogen-
free by heating at 200C for 90 min. The sterile crystals were resuspended by
brief sonication in DMEM prior to use. For all experiments, cells were treated
with BCP crystals at a concentration of 18 mg/cm2, consistent with the concen-
trations of BCP crystals found in OA synovial ﬂuids.EP3 Forward TCT CCG CTC CTG ATA ATG ATG TT
Reverse TCT GCT TCT CCG TGT GTG TCT TCELL CULTUREEP4 Forward CGA CCT TCT ACA CGC TGG TAT G
Reverse CCG GGC TCA CCA ACA AAG TSynovial tissue was obtained from four primary OA patients undergoing
joint replacement surgery. Informed consent was obtained from all patients.Ethical approval was granted by the National Orthopaedic Hospital Ethics
Committee. The synovial tissue was minced and enzymatically digested by
1.5 mg/ml collagenase in DMEM for 90 min at 37C. Then 0.5% trypsin in
DMEM was added for a further 30 m incubation. Cells were centrifuged at
1000 g for 5 min and washed with phosphate-buffered saline/DMEM four
times. Cells were resuspended, grown and maintained in DMEM containing
10% FBS, 1% penicillin/streptomycin/fungizone and 1% sodium pyruvate, in
a humidiﬁed incubator at 37C with 5% carbon dioxide/95% air. All cultures
used were ﬁfth or earlier passage cells. All experiments were repeated on at
least three different samples.RNA EXTRACTION, REVERSE TRANSCRIPTION AND
REAL-TIME POLYMERASE CHAIN REACTION (PCR)RNA was isolated and reverse transcribed as previously described32.
Real-time RT-PCR was carried out using an ABI 7500 Sequence Detector
(Applied Biosystems, UK). Using 18S ribosomal RNA (18S) as an internal
control, relative quantitation of the amount of target copy in unknown sam-
ples is accomplished using the standard curve method. SYBR Green chem-
istry was employed and primers were used at ﬁnal concentration of 300 nM.
Primer sequences for PGES and EP receptors are given in Table I. 18S
primers and probe mix and universal master mix were purchased from Ap-
plied Biosystems and used as per the manufacturer’s instructions.PROSTANOID AGONISTS AND ANTAGONISTSL-161982 is a selective EP4 receptor antagonist. CAY10399, is a selective
EP2 receptor agonist that is 25 times more potent than butaprost. Forskolin
is a direct activator of adenylate cyclase, resulting in an increase in intracel-
lular cAMP. These compounds were used at concentrations of 1 mM, 10 mM
and 30 mM respectively. PGE2 was used at concentrations of 0.1 mM unless
otherwise speciﬁed. Aspirin, SC-236 (a COX-2 selective inhibitor) and SC-
560 (a COX-1 selective inhibitor) were used at concentrations of 200 mM,
1 mM and 1 mM respectively. Ethanol (0.1%) was used as vehicle control.
Choice of concentrations and timing of administration of inhibitors was in-
formed by prior experiments, cytotoxicity assays, the available literature and
the manufacturers’ instructions.WESTERN BLOTTINGSamples containing equal protein concentrations were electrophoresed
on 15% sodium dodecyl sulfate (SDS) polyacrylamide gels and proteins
were transferred to nitrocellulose membranes over 2 h. Membranes were
blocked in 3% bovine serum albumin. The membranes were then incubated
for 3 h with 1:500 dilution of mouse monoclonal anti-human mPGES1 pri-
mary antibody (SPI-Bio, France). Secondary peroxidase-conjugated anti-
mouse immunoglobulin was used at a dilution of 1/10,000. Immunoreactive
bands were detected using enhanced chemiluminescence reagents en-
hanced chemiluminescence (ECL)-plus (Amersham, UK).STATISTICAL ANALYSISTo simplify the graphical presentation of the data, all quantitative data are
expressed as mean fold change  the standard error of the mean (S.E.M.)
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t-test was employed for statistical analysis. P values less than 0.05 were
considered signiﬁcant.ResultsBCP CRYSTALS UPREGULATE mPGES1 IN HFF BUT NOT IN
OASFmPGES1 mRNA expression in OASF was measured by
real-time PCR. Incubation of OASF with BCP crystals for
various times (1e32 h) did not signiﬁcantly inﬂuence
mPGES1 mRNA expression in OASF [Fig. 1(A)]. In addi-
tion, stimulation with phorbol myristate acetate (PMA), pre-
viously reported to upregulate mPGES1 mRNA
expression37,38, did not augment mPGES1 mRNA expres-
sion in OASF [Fig. 1(A)]. In contrast, in HFF, a signiﬁcant
threefold and fourfold induction of mPGES1 mRNA expres-
sion was evident at 4 and 7 h following BCP crystal stimu-
lation, respectively [Fig. 1(B)].mPGES1 IS OVER-EXPRESSED IN OASF AS COMPARED
TO HFFFig. 2. (A) Comparison of mPGES1 mRNA expression between
HFF and OASF. Untreated HFF (HFF U), BCP crystal-treated
HFF (HFF B) and untreated OASF (OASF U) were incubated for
7 h. mPGES1 mRNA expression was measured by real-time
PCR. Results are expressed as mPGES1 mRNA expression nor-
malised to 18S levels, then expressed as fold change over the
values for the untreated HFF. Therefore, the untreated HFF as-
sumes a value of 1 (mean S.E.M., n¼ 3, *P< 0.05, **P< 0.01 vsmPGES1 mRNA expression was compared in HFF and
OASF by real-time PCR [Fig. 2(A)]. Basal mPGES1 expres-
sion in untreated OASF was 30-fold higher than in untreated
HFF. Even at 7 h post-stimulation with BCP crystals, the
timepoint of maximum induction of mPGES1 in HFF by
BCP crystals, mPGES1 expression is approximately 10-
fold lower than in untreated OASF.Fig. 1. mPGES1 mRNA expression in HFF but not OASF is aug-
mented by treatment with BCP crystals. (A) OASF were treated
with BCP crystals (BCP 1 h-BCP 32 h) or left untreated for
1e32 h, or stimulated with PMA. (B) HFF were treated with BCP
crystals or left untreated for 4 (BCP 4 h) or 7 h (BCP 7 h). mPGES1
mRNA expression was measured by real-time PCR, normalised to
18S values and expressed as fold change in the treated cells over
untreated control incubated for the same period of time. Therefore,
the values of the untreated controls are 1. (A: mean S.E.M., n¼ 4;
B: mean S.E.M., n¼ 3, *P< 0.05).
HFF U). (B) Relative expression of PGE2 synthases in OASF.
Real-time PCR was used to quantify the mRNA expression levels
of mPGES1, cPGES and mPGES2 in untreated OASF. Levels
were normalised to 18S and then mRNA expression for each syn-
thase was calculated relative to the expression of mPGES2 mRNA
(mean S.E.M., n¼ 4).RELATIVE EXPRESSION OF PROSTAGLANDIN SYNTHASES
IN OASFThe relative expression of mPGES1, mPGES2 and
cPGES in untreated OASF was measured by real-time
PCR [Fig. 2(B)]. The mean relative mRNA expression was
mPGES1: cPGES: mPGES2¼ 22: 9: 1. Expression of
cPGES and mPGES2 mRNA in OASF was unchanged by
treatment with BCP crystals (data not shown).EP4 RECEPTOR EXPRESSION IS DOWNREGULATED BY BCP
CRYSTALS IN OASF BUT NOT HFFReal-time PCR was used to quantify the mRNA
expression levels of the EP1, EP2, EP3, and EP4 recep-
tors in untreated OASF. EP4 was the most highly
expressed EP receptor with appreciable expression of
EP2 also found; there was negligible expression of EP1
and EP3 (data not shown). This pattern of EP receptor
expression is consistent with that previously reported
for RA synoviocytes20. EP4 receptor mRNA expression
was downregulated up to 2.5-fold in OASF in response
to BCP crystal treatment [Fig. 3(A)]. In contrast, EP4
expression was increased approximately twofold in HFF
by BCP crystal stimulation [Fig. 3(B)]. Expression of
EP1, EP2 and EP3 receptor mRNA was not signiﬁcantly
altered when OASF were treated with BCP crystals (data
not shown).
Fig. 3. Expression of the EP4 receptor mRNA in [A] OASF and [B]
HFF following stimulation with BCP crystals. OASF were treated
with BCP crystals for 1e32 h. HFF were treated with BCP crystals
for 4 h or left untreated. EP4 receptor mRNA expression was mea-
sured by real-time PCR, normalised to 18S values and then ex-
pressed as fold change over the value obtained for the untreated
control incubated for the same period of time (mean  S.E.M.,
n¼ 3, *P< 0.05, **P< 0.01).
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CRYSTAL-TREATED OASFIn BCP crystal-treated OASF, EP4 receptor mRNA ex-
pression was downregulated approximately twofold in
OASF in response to exogenous PGE2 treatment and upre-
gulated by aspirin and SC-236 (Fig. 4). The addition of ex-
ogenous PGE2 overcame the effect of aspirin and SC-236.
The downregulatory effect of PGE2 on EP4 mRNA expres-
sion was diminished by treatment with L-161982, a selective
EP4 receptor antagonist.Fig. 4. Effect of PGE2 on EP4 mRNA expression in BCP crystal-stimulated
(ASA), 1 mM SC-236 (236) and 10 mM L-161982 (L1), prior to treatment w
real-time PCR, normalised to 18S values and then expressed as fold cha
the same period of time. Therefore the untreated control (far left column)PGE2 UPREGULATES mPGES1 EXPRESSION VIA THE
cAMP-DEPENDENT EP2/EP4 RECEPTORSTreatment with PGE2 signiﬁcantly increased mPGES1
expression in both BCP crystal-treated and untreated
OASF [Fig. 5(A)]. Increased mPGES1 protein production
following addition of PGE2 to BCP crystal-stimulated
OASF was demonstrated by western blotting [Fig. 5(B)].
Pre-treatment with L-161982 diminished the upregulation
of mPGES1 mRNA expression seen in OASF in response
to PGE2 stimulation in both untreated and BCP crystal-
treated OASF [Fig. 5(A)]. Following the addition of PGE2,
there was an approximately threefold higher level of
mPGES1 expression in BCP crystal-treated OASF vs
OASF not treated with BCP crystals, which was comparable
to the mPGES1 upregulation seen with BCP crystal stimu-
lation in HFF. In contrast to its effect on mPGES1, PGE2
stimulation did not affect mRNA expression of mPGES2
or cPGES either in untreated or BCP crystal-treated
OASF (data not shown).
Figure 5(C) demonstrates that treatment with CAY10399,
an EP2 selective agonist, and forskolin, a direct adenylate
cyclase agonist, both replicated the upregulation of
mPGES1 mRNA expression seen in OASF in response to
PGE2 stimulation. Administration of aspirin, SC-236 or
SC-560 did not signiﬁcantly inﬂuence the level of mPGES1
mRNA expression in either untreated or BCP crystal-treated
OASF (data not shown).Discussion
Enhanced PGE2 synthesis in the setting of inﬂammation
is thought to be predominantly mediated by the sequential
action of COX-2 and mPGES1. Both of these enzymes
are generally expressed at low levels at baseline, are co-or-
dinately upregulated by pro-inﬂammatory stimuli6,7,9e11,39
and downregulated by dexamethasone11. The functional
coupling between COX-2 and mPGES1 is underlined by
the preferential utilisation of COX-2 derived PGH2 by
mPGES110 and their co-localisation to the perinuclear
membrane10,40.
Given the demonstrated ability of BCP crystals to upregu-
late COX-2 in HFF32 and OASF35, it was anticipated that
upregulation of mPGES1 would also occur in response to
BCP crystals. Indeed, there was up to fourfold upregulation
of mPGES1 noted in BCP crystal-treated HFF. ConsistentOASF. OASF were treated with 1 mM PGE2 and/or 200 mM aspirin
ith BCP crystals. EP4 receptor mRNA expression was measured by
nge over the value obtained for the untreated control incubated for
assumed a value of 1 (mean S.E.M., n¼ 3, *P< 0.05, **P< 0.01).
Fig. 5. Effect of PGE2 on expression of mPGES1. (A) OASF were
treated with 1 mM PGE2 and/or 10 mM L-161982 (L1), prior to treat-
ment with BCP crystals. mPGES1 mRNA expression was mea-
sured by real-time PCR, normalised to 18S values and expressed
as fold change over the values obtained for the untreated control
cells. Therefore the value for the untreated samples (most leftward
column) was 1 (mean S.E.M., n¼ 3, *P< 0.05 vs untreated OASF,
$P< 0.05 vs OASF treated only with BCP crystals, #P< 0.05 vs
OASF treated only with BCP crystals and PGE2). (B) Western blot-
ting for mPGES1. OASF were treated as indicated and incubated
for 24 h. PGES1 protein was measured by western blotting of cell
lysates, using a monoclonal antibody to mPGES1. Equal protein
loading, as determined by Bradford assay were loaded onto 15%
SDS_PAGE gels. (C) Effect of EP2 and cAMP agonists on
mPGES1 mRNA expression in OASF. OASF were incubated with
BCP crystals with or without PGE2, CAY10399 (CAY) or forskolin
(FOR). mPGES1 mRNA expression was measured by real-time
PCR, normalised to 18S values and expressed as fold change of
the values for the agonist treated cells over the values seen with
BCP alone. Therefore the value for OASF treated with BCP crystals
alone is 1 (mean S.E.M., n¼ 3, *P< 0.05).
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Egr-1, a key transcription factor for mPGES1 expression,
in human ﬁbroblasts33. However, mPGES1 mRNA expres-
sion is not enhanced in OASF in response to BCP crystal
stimulation. This differential response to BCP crystal stimu-
lation may be explained by the fact that baseline expression
of mPGES1 in OASF is over 30-fold greater than in HFF. In-
deed, mPGES1 is more abundantly expressed in unstimu-
lated OASF than the ‘constitutive’ PGE synthases,
cPGES and mPGES2. Increased expression of mPGES2
in tissues with low levels of mPGES1 expression and vice
versa has been previously reported12. Strong mPGES1expression has been demonstrated on immunohistochemi-
cal analysis of RA synovium19. Cheng et al. found that
mPGES1 expression could be induced by IL1b in OASF,
but mPGES1 was detectable in untreated cells5. OASF
have not previously been compared with other cell types
as regards mPGES1 expression. mPGES1 is constitutively
expressed in certain tissues2,3, but the level of mPGES1 ex-
pression in non-diseased synovium has not been estab-
lished. It is conceivable that chronic upregulation of
mPGES1 occurs in OASF in vivo, as a result of pro-inﬂam-
matory stimuli, such as cytokines (e.g., IL1) and BCP
crystals.
Similar to RA synoviocytes20, EP4 and EP2 are the only
EP receptors appreciably expressed in OASF. Regulation
of the EP receptors41e43 has previously been described;
differential regulation of the EP2 and EP4 receptors has
previously been demonstrated in response to
lipopolysaccharide43. Expression of EP4 (but not EP2) re-
ceptor mRNA is downregulated by BCP crystals in OASF,
but not in HFF. This downregulatory effect of BCP crystals
on EP4 receptor expression was replicated by treatment of
OASF with PGE2. EP4 receptor mRNA expression was in-
creased by treatment with aspirin and SC-236, an effect that
was overcome by treatment with PGE2. However, the
downregulatory effect of PGE2 on EP4 expression was
blocked by L-161982, a speciﬁc EP4 receptor antagonist.
This suggests that the likely mechanism of downregulation
of EP4 receptor mRNA expression seen in response to
BCP crystals in OASF is through a direct effect of PGE2
on the EP4 receptor.
Treatment of OASF with PGE2 results in a signiﬁcant up-
regulation of mPGES1 transcript, in particular in cells also
treated with BCP crystals, implying the presence of a posi-
tive feedback loop in the generation of PGE2 in OASF. This
response was not observed for cPGES or mPGES2. This
effect of PGE2 is signiﬁcantly diminished by pre-treatment
with L-161982, implicating the EP4 receptor in this
response. In this regard it is interesting to note that PGE2-
EP4 signalling has been shown to induce functional expres-
sion of Egr-144, a key transcription factor for mPGES1
expression34. Thus, the downregulation of the EP4 receptor
seen in BCP crystal-treated OASF may suppress the posi-
tive feedback mechanism described above and could po-
tentially explain the discordant responses to BCP crystals
between OASF and HFF as regards mPGES1 upregulation,
as well as the lack of an observed inhibitory effect of COX
inhibition on mPGES1 expression in BCP crystal-stimulated
OASF. The effects of the EP4 receptor downregulation is
only overcome by the addition of an excess of PGE2, at
which time a stimulatory effect of BCP crystals on mPGES1
expression in OASF becomes apparent. One potential hy-
pothesis is that the mechanism of EP4 receptor downregu-
lation exists as a restraint on this positive feedback loop and
is facilitated in OASF by the increased basal expression of
mPGES1 and consequent PGE2 production. The upregula-
tion of mPGES1 by PGE2 is replicated by CAY10399, an
EP2 receptor agonist, suggesting that EP2 may also con-
tribute to the upregulation of mPGES1 by PGE2. Treatment
with forskolin, a direct adenylate cyclase activator also
leads to a signiﬁcant induction of mPGES1 in OASF, reﬂect-
ing the fact that the EP2 and EP4 receptors mediate their
cellular effects principally via increased cAMP production.
Similar results were obtained in RA synoviocytes20.
As mPGES1 appears to be the major PGE synthase con-
tributing to PGE2 production in the setting of inﬂammation, it
has been proposed as a therapeutic target in inﬂammatory
diseases45. Selective inhibition of mPGES1 could prevent
691Osteoarthritis and Cartilage Vol. 17, No. 5PGE2 production in response to inﬂammatory stimuli, while
permitting ongoing production of PGE2 (by the constitutive
PGES) and of other prostanoids, that may be required for
homeostatic purposes. This could theoretically result in sig-
niﬁcantly less toxicity than is seen with NSAIDs. The rela-
tive overexpression of mPGES1 in OASF identiﬁes it as
a potential therapeutic target in OA. In this regard it is inter-
esting to note the ﬁndings in the mPGES1 knockout
mouse17,18. There were no apparent adverse conse-
quences of the lack of mPGES1, but there was signiﬁcant
amelioration of the clinical and histological features of an in-
ﬂammatory arthritis model. However, the precise contribu-
tion of PGE2 to conditions such as OA is not known, and
PGE2 can mediate an attenuation of inﬂammation in certain
situations26,27. Furthermore, as mPGES1 is constitutively
expressed in the kidney, urogenital tract and reproductive
organs2,3 and the potential for a compensatory increase in
the activity of other PGES (as occurs with COX) has not
been examined, caution must be maintained at present in
promoting mPGES1 inhibition as a therapeutic anti-inﬂam-
matory strategy.
This data suggests that EP4 may also be a therapeutic
target in OA. However, enthusiasm for this approach is
tempered by the fact that the effects of PGE2 are often
mediated through more than one EP receptor, and that
PGE2-EP4 signalling may mediate anti-inﬂammatory effects
in some settings26,27 and is involved in gastric mucosal
protection46,47.
In summary, we have demonstrated discordance be-
tween COX-2 and mPGES1 responses to BCP crystal stim-
ulation in OASF; this may be explained by PGE2-mediated
downregulation of EP4 receptor expression in BCP crystal-
stimulated OASF. These observations emphasize the
complex nature of the regulation of PG production, and
underline the challenges faced in selectively targeting
pathways that could more speciﬁcally inhibit the deleterious
effects of PGs in OA.Conﬂict of interest
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